The Food and Drug Administration (FDA) has granted Fast Track designation to ecopipam (Emalex Biosciences), an investigational agent for the treatment of Tourette syndrome (TS).
An expert subcommittee of the AAN has released an updated evidence-based clinical practice guideline on treating Tourette syndrome and other chronic tic disorders.
Antipsychotics have been shown to reduce tic severity, as has behavior therapy. However, the mechanisms behind the efficacy of behavior therapy have yet to be clarified by research.
The FDA has granted Orphan Drug Designation to Valbenazine.
Maternal tobacco smoking during pregnancy has previously been linked with numerous long-term neurodevelopmental abnormalities and child behavioral problems.
